Sugi Predict

Sugi Predict / Compounds / SCHEMBL207017

SCHEMBL207017

SCHEMBL207017

O=C(O)c1cccc(-c2ccccn2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.69
▸ KDM6B O15054 1/20 0.69
▸ KDM4A O75164 1/20 0.69
▸ KDM5C P41229 1/20 0.69
▸ KDM4C Q9H3R0 1/20 0.69
▸ KDM2A Q9Y2K7 1/20 0.69
▸ KDM3A Q9Y4C1 1/20 0.69
▸ KMO O15229 2/20 0.63
▸ KAT6A Q92794 2/20 0.57
▸ CD74 P04233 1/20 0.54
▸ MIF P14174 1/20 0.54
▸ LDHA P00338 1/20 0.53
▸ CYP2A6 P11509 1/20 0.52
▸ RXRA P19793 1/20 0.51
▸ RXRB P28702 1/20 0.51
▸ DHODH Q02127 1/20 0.51
▸ CNR1 P21554 1/20 0.51
▸ CSNK2A2 P19784 1/20 0.51
▸ CSNK2B P67870 1/20 0.51
▸ PIN1 Q13526 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800516 1.00 KDM4E (0.69) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL28830424 0.89 KDM4E (0.64) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL28404844 0.89 KDM4E (0.64) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL9665770 0.89 KDM5C (0.62) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL16817841 0.87 ATM (0.59) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL16108931 0.87 KAT6A (0.56) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL5108635 0.87 KAT6A (0.55) KDM4EKDM6BKDM4AKDM5CKDM4C
Ethylene SCHEMBL28452817 0.86 KDM4E (0.60) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL2457556 0.85 KAT6A (0.54) KDM4EKDM6BKDM4AKDM5CKDM4C
SCHEMBL940696 0.85 KMO (0.62) KDM4EKDM6BKDM4AKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
US-12570675-B2 Boronic acid compounds LG CHEM, LTD. (KR) 2026-03-10 — — US disclosed
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. 2026-01-29 — — US disclosed
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient KAINOS MEDICINE, INC. (KR) 2026-01-27 — — US disclosed
US-20250188092-A1 RIFAMYCIN ANALOGS THE PENN STATE RESEARCH FOUNDATION 2025-06-12 — — US disclosed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN disclosed
WO-2024086132-A1 PROTACS TARGETING VIRAL ENZYMES FOR PRECISE TREATMENT OF COVID-19 OHIO UNIVERSITY (US) 2024-04-25 — — WO disclosed
US-20240101579-A1 BORONIC ACID COMPOUNDS LG CHEM, LTD. (KR) 2024-03-28 — — US disclosed
CN-114395551-B Preparation of magnetic material-metal organic framework-tyrosinase complex and method for dephenolization 深圳大学 2024-01-02 — — CN disclosed
CN-117147653-A Electrochemical luminescence polypeptide sensing method for detecting matrix metalloproteinase 陕西师范大学 2023-12-01 — — CN disclosed
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-17 — — US disclosed
WO-2008079277-A1 CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-07-03 — — WO disclosed
EP-1093367-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2003-03-05 — — EP disclosed
US-6369077-B1 OSTEOPOROSIS, PERIODONTITIS, AND ARTHRITIS SMITHKLINE BEECHAM CORPORATION 2002-04-09 — — US disclosed
EP-0991753-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2001-07-11 — — EP disclosed
EP-1093367-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-04-25 — — EP disclosed
CN-1255162-A Protease inhibitors SMITHKLINE BEECHAM CORP (US) 2000-05-31 — — CN disclosed
EP-0991753-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-04-12 — — EP disclosed
WO-1999066925-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1999-12-29 — — WO disclosed
WO-1998050534-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027106-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 KDM4E 390/4885KDM6B 260/4885KDM4A 1002/4885
US-12570675-B2 Boronic acid compounds PSMB6, PSMB3, PSMB2 KDM4E 3458/4885KDM6B 1752/4885KDM4A 3141/4885
US-20240101579-A1 BORONIC ACID COMPOUNDS PSMB11, PSMB1, BACH1 KDM4E 2004/4885KDM6B 1043/4885KDM4A 1569/4885
US-20080171754-A1 Certain pyrazoline derivatives with kinase inhibitory activity MAP3K5, MAP4K5, MAP3K20 KDM4E 1270/4885KDM6B 2320/4885KDM4A 1915/4885
US-20250188092-A1 RIFAMYCIN ANALOGS CYP3A4, CYP4B1, CYP2C9 KDM4E 2442/4885KDM6B 3319/4885KDM4A 2420/4885
US-12534452-B2 N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient IRAK4, IRAK1, IRAK2 KDM4E 130/4885KDM6B 164/4885KDM4A 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.